← SynDRA
MERESTINIB
SynDRA canonical compound SYN0038267 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
| Primary target(s) | MET | MST1R |
| Mechanism of action | MET inhibitor |
All known targets
- MET
- MST1R
- AXL
- DDR1
- FLT3
- MERTK
- TEK
- TIE1
Mechanisms of action (all sources)
- MET INHIBITOR
- Hepatocyte growth factor receptor inhibitor
- AXL INHIBITOR
- DDR1 INHIBITOR
- FLT3 INHIBITOR
- MST1R INHIBITOR
- MERTK INHIBITOR
- TEK INHIBITOR
- TIE1 INHIBITOR
- MET MODULATOR
Cross-references
Synonyms
- LY-2801653
- LY2801653
- UNII-5OGS5K699E
- N-(3-fluoro-4-((1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl)oxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide
- 5OGS5K699E
- N-(3-Fluoro-4-{[1-Methyl-6-(1h-Pyrazol-4-Yl)-1h-Indazol-5-Yl]oxy}phenyl)-1-(4-Fluorophenyl)-6-Methyl-2-Oxo-1,2-Dihydropyridine-3-Carboxamide
- C30H22F2N6O3
- Merestinib [USAN]
- SCHEMBL679002
- LY2801653 (Merestinib)
- GTPL9841
- CHEMBL3545307
- QCR-139
- DTXSID20659635
- SYN1222
- QHADVLVFMKEIIP-UHFFFAOYSA-N
- LY 2801653
- N-[3-fluoro-4-[1-methyl-6-(1H-pyrazol-4-yl)indazol-5-yl]oxyphenyl]-1-(4-fluorophenyl)-6-methyl-2-oxopyridine-3-carboxamide
- Merestinib (LY2801653)
- 3-Pyridinecarboxamide, N-(3-fluoro-4-((1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl)oxy)phenyl)-1-(4-fluorophenyl)-1,2-dihydro-6-methyl-2-oxo-
- N-(3-Fluoro-4-(1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yloxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide
- L1X
- MERESTINIB [INN]
- Merestinib (USAN/INN)
- MERESTINIB [WHO-DD]
- HMS3741E21
- BCP06826
- EX-A1264
- BDBM50172078
- NSC772197
- NSC800788
- s7014
- ZINC95926668
- AKOS027323283
- CCG-270011
- CS-1192
- DB12381
- NSC-772197
- NSC-800788
Look up MERESTINIB in the interactive SynDRA portal →